Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.

Colwell CW Jr, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW; EXULT B Study Group.

J Bone Joint Surg Am. 2005 Oct;87(10):2169-77.

PMID:
16203879
2.
3.

Clinical experience with ximelagatran in orthopaedic surgery.

Eriksson B.

Drugs. 2004;64 Suppl 1:27-35. Review.

PMID:
15586625
4.
5.

Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.

Koscielny J, Kiesewetter H, Jörg I, Harenberg J.

Clin Appl Thromb Hemost. 2007 Jul;13(3):299-307. Review.

PMID:
17636192
6.

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era...

Mohapatra R, Tran M, Gore JM, Spencer FA.

Am Heart J. 2005 Jul;150(1):19-26. Review.

PMID:
16084146
7.

Ximelagatran.

Choudhury A, Goyal D, Lip GY.

Drugs Today (Barc). 2006 Jan;42(1):3-19. Review.

PMID:
16511607
8.
9.

Ximelagatran: an orally active direct thrombin inhibitor.

Gulseth MP.

Am J Health Syst Pharm. 2005 Jul 15;62(14):1451-67. Review.

PMID:
15998925
10.

Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.

Albers GW; SPORTIF Investigators.

Am J Manag Care. 2004 Dec;10(14 Suppl):S462-9; discussion S469-73. Review.

11.

Ximelagatran: direct thrombin inhibitor.

Ho SJ, Brighton TA.

Vasc Health Risk Manag. 2006;2(1):49-58. Review.

12.

[Ximelagatran for treatment of venous thromboembolism].

Harenberg J, Fenyvesi T, Jörg I.

Hamostaseologie. 2002 Aug;22(3):25-9. Review. German.

PMID:
12215758
13.
14.

Oral direct thrombin inhibitors in clinical development.

Gustafsson D.

J Intern Med. 2003 Oct;254(4):322-34. Review.

15.

The direct thrombin inhibitor melagatran/ximelagatran.

Brighton TA.

Med J Aust. 2004 Oct 18;181(8):432-7. Review.

PMID:
15487959
16.

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.

Salazar CA, Malaga G, Malasquez G.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005981. doi: 10.1002/14651858.CD005981.pub2. Review.

PMID:
20393944
17.

Ximelagatran--a promising new drug in thromboembolic disorders.

Petersen P.

Curr Pharm Des. 2005;11(4):527-38. Review.

PMID:
15725069
18.

Ximelagatran: a new oral anticoagulant.

Hrebickova L, Nawarskas JJ, Anderson JR.

Heart Dis. 2003 Nov-Dec;5(6):397-408. Review.

PMID:
14633322
20.

The role of ximelagatran in the treatment of venous thromboembolism.

Schulman S.

Pathophysiol Haemost Thromb. 2005;34 Suppl 1:18-24. Review.

Supplemental Content

Support Center